|1.||Beitler, B: 1 article (10/2006)|
|2.||Llacer, P D: 1 article (10/2006)|
|3.||Chamone, D A F: 1 article (10/2006)|
|4.||Dulley, F L: 1 article (10/2006)|
|5.||Pereira, J: 1 article (10/2006)|
|6.||Chaoubah, A: 1 article (10/2006)|
|7.||Hallack Neto, A E: 1 article (10/2006)|
|8.||Macedo, M C M A: 1 article (10/2006)|
|9.||Qiu, Meng: 1 article (04/2005)|
|10.||Li, Lu: 1 article (04/2005)|
|1.||Non-Hodgkin Lymphoma (Lymphosarcoma)
11/01/1995 - "Administration of rhG-CSF increases complete remission rates after CHOP and ProMACE/CytaBOM for non-Hodgkin's lymphoma: a pilot study. "
09/01/1998 - "Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype."
09/01/1998 - "Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. "
03/15/1997 - "A pilot study on the use of the ProMACE-CytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. "
03/15/1997 - "The Gruppo Italiano per lo Studio dei Linfomi conducted a study to evaluate the efficacy and toxicity of a third-generation polychemotherapeutic regimen, ProMACE-CytaBOM, as a first-line therapy in a selected group of patients with advanced follicular non-Hodgkin's lymphoma (Fo-NHL) who were younger than 60 years. "
03/01/1994 - "ProMACE-CytaBOM may represent improved treatment for aggressive lymphomas, in terms of duration of response and survival, but a longer follow up is needed."
01/01/2000 - "In conclusion, in this study CEOP-B/VIMB was not superior to ProMACE-CytaBOM in aggressive lymphomas and the alternating strategy failed to improve outcome of poor risk patients in which newer more aggressive treatments are needed."
11/15/1999 - "We showed in a phase I trial that the maximum tolerated dose of the ProMACE-CytaBOM regimen in patients with aggressive lymphoma was 200% (Gordon et al, J Clin Oncol 14:1275, 1996). "
11/15/1999 - "A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity."
11/01/1996 - "In conclusion, in this study ProMACE-CytaBOM has not proved to be superior to CHOP in aggressive lymphomas. "
|3.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
07/01/1989 - "We conclude that ProMACE CytaBOM represents a highly effective and easy-to-administer regimen in patients with large cell lymphoma."
07/01/1989 - "ProMACE-CytaBOM: combination chemotherapy for diffuse large cell lymphoma."
10/01/2006 - "We conclude that both the CHOP and ProMACE-CytaBOM protocols can be used to treat diffuse large B-cell lymphoma patients, although the CHOP protocol is preferable because of its lower cost and lower toxicity."
12/01/1990 - "ProMACE-CytaBOM may represent improved treatment for diffuse large-cell lymphoma, but the modest differences compared with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) indicate the need for a prospective randomized comparative trial."
07/01/1989 - "ProMACE CytaBOM, a polychemotherapy regimen consisting of cyclophosphamide, doxorubicin, etoposide cytozar, bleomycin, vincristine, methotrexate and prednisone was administered on an outpatient basis to six consecutive patients with diffuse large cell lymphoma. "
02/01/1995 - "rhG-CSF administration reduced the frequency of infection complications, and there was no obvious difference in it's frequency between the CHOP-treated and the ProMACE/CytaBOM-treated groups when administered with rhG-CSF, thereby indicating that third generation therapy for NHL may be safely completed in Japanese in combination with rhG-CSF administration. "
03/01/1986 - "carinii infection in patients receiving ProMACE-CytaBOM was not ascertained. "
02/01/1995 - "In this multi-center study, we studied the prophylaxtic effect of rhG-CSF administration on infection complications in patients with non-Hodgkin malignant lymphoma, who received cytotoxic chemotherapies (CHOP or ProMACE/CytaBOM). "
03/01/1986 - "A significantly greater prevalence of interstitial pulmonary infiltrates and Pneumocystis carinii pneumonitis occurred on one arm of a randomized study comparing ProMACE-CytaBOM (prednisone, methotrexate with leucovorin, doxorubicin, cyclophosphamide, etoposide; cytarabine, bleomycin, vincristine, methotrexate with leucovorin) to ProMACE-MOPP (ProMACE, mechlorethamine, vincristine, prednisone, procarbazine) chemotherapy in patients with lymphoma. "
|5.||Granulocyte Colony-Stimulating Factor (G-CSF)
|6.||Etoposide (VP 16)
|10.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)